Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

257 та иш

Иш: Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

  1. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

    Bertram Pitt, Faı̈ez Zannad, Willem J. Remme +5

    Мақола19993 иқтибос
    ABI

  2. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

    Michael Böhm, Helmut Schumacher, Koon Teo +10

    Шарҳ мақола20173 иқтибос
    ABI

  3. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity

    Sadiya S. Khan, Hongyan Ning, John T. Wilkins +5

    Мақола20183 иқтибос
    ABI

  4. Diagnosis and treatment of arterial hypertension [Guidelines]

    И Е Чазова, Yu. V. Zhernakova

    Мақола20193 иқтибос
    ABI

  5. In-Hospital Outcomes of Percutaneous Coronary Interventions in Extremely Obese and Normal-Weight Patients

    Saeed Payvar, Sunghee Kim, Sunil V. Rao +4

    Мақола20132 иқтибос
    ABI

  6. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes

    Hussam Abuissa, Philip G. Jones, Steven P. Marso +1

    Шарҳ мақола20052 иқтибос
    ABI

  7. Combining Body Mass Index With Measures of Central Obesity in the Assessment of Mortality in Subjects With Coronary Disease

    Thais Coutinho, Kashish Goel, Daniel Correa de +16

    Мақола20132 иқтибос
    ABI

  8. Aggressive Risk Factor Reduction Study for Atrial Fibrillation and Implications for the Outcome of Ablation

    Rajeev K. Pathak, Melissa E. Middeldorp, Dennis H. Lau +10

    Мақола20142 иқтибос
    ABI

  9. Is There an Obesity Paradox After Percutaneous Coronary Intervention in the Contemporary Era?

    T. Lancefield, David Clark, Nick Andrianopoulos +9

    Мақола20102 иқтибос
    ABI

  10. Risk of Myocardial Infarction and Heart Failure Among Metabolically Healthy But Obese Individuals

    Bjørn Mørkedal, Lars J. Vatten, Pål Romundstad +2

    Мақола20132 иқтибос
    ABI

  11. Effect of uncomplicated obesity on QT interval in young men

    Erol Arslan, Ömer Yiğiner, İrfan Yavaşoğlu +3

    Мақола20102 иқтибос
    ABI

  12. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation

    Christopher X. Wong, Thomas Sullivan, Michelle T. Sun +9

    Мақола20152 иқтибос
    ABI

  13. Electrocardiographic QRS Fragmentation as a Marker for Myocardial Fibrosis in Hypertrophic Cardiomyopathy

    Tetsuo Konno, Kenshi Hayashi, Noboru Fujino +10

    Мақола20152 иқтибос
    ABI

  14. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

    John J McMurray, John J.V. McMurray, Steven M Haffner +51

    Мақола20102 иқтибос
    ABI

  15. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome

    Sebastien X Joncas, Paul Poirier, Jean‐Luc Ardilouze +3

    Мақола20132 иқтибос
    ABI

  16. Effect of Obesity and Overweight on Left Ventricular Diastolic Function

    C Allison Russo, Zhezhen Jin, Shunichi Homma +4

    Мақола20112 иқтибос
    ABI

  17. Patients with Metabolic Syndrome Have Prolonged Corrected QT Interval (QTc)

    Weiju Li, Yongyi Bai, Kai Sun +7

    Мақола20092 иқтибос
    ABI

  18. Pericardial fat is associated with ventricular tachyarrhythmia and mortality in patients with systolic heart failure

    Cho‐Kai Wu, Hao‐Yuan Tsai, Mao‐Yuan Su +5

    Мақола20152 иқтибос
    ABI

  19. The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation

    Usha B. Tedrow, David Conen, Paul M. Ridker +5

    Мақола20102 иқтибос
    ABI

  20. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial

    Sverre E. Kjeldsen, Eivind Berge, Sripal Bangalore +8

    Мақола20152 иқтибос
    ABI

  21. A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide

    Matthew R. Weir, Willa A. Hsueh, Shawna D. Nesbitt +7

    Мақола20112 иқтибос
    ABI

  22. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study

    Renate B. Schnabel, Xiaoyan Yin, Philimon Gona +12

    Мақола20152 иқтибос
    ABI

  23. Metabolic syndrome update

    Scott M. Grundy

    Шарҳ мақола20152 иқтибос
    ABI

  24. Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation

    Hany S. Abed, Gary Wittert, Darryl P. Leong +10

    Мақола20132 иқтибос
    ABI

  25. Relief of Cardiorespiratory Symptoms and Increased Physical Activity After Surgically Induced Weight Loss

    Kristjan Karason, Anna Karin Lindroos, Kaj Stenlöf +1

    Мақола20002 иқтибос
    ABI